Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis

Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter.

[1]  D. Vidal,et al.  Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain , 2018, The Journal of dermatological treatment.

[2]  D. Ioannides,et al.  Secukinumab survival and long‐term efficacy in patients with plaque psoriasis: real‐life data from a tertiary hospital in Greece , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  W. Liao,et al.  Secukinumab in the treatment of psoriasis: patient selection and perspectives , 2018, Psoriasis.

[4]  K. Peris,et al.  Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation , 2018, Expert Opinion on Biological Therapy.

[5]  M. Augustin,et al.  Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  L. Skov,et al.  Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study , 2017, Dermatologic therapy.

[7]  S. Chimenti,et al.  Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  L. Naldi,et al.  Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  A. Kimball,et al.  Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy☆☆☆ , 2016, International journal of women's dermatology.

[10]  M. Casado,et al.  The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. , 2016, Actas dermo-sifiliograficas.

[11]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[12]  P. Amerio,et al.  Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. , 2016, Acta dermato-venereologica.

[13]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[14]  Jashin J. Wu,et al.  Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review. , 2015, Journal of the American Academy of Dermatology.

[15]  R. Romero-Jimenez,et al.  Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting. , 2015, Actas dermo-sifiliograficas.

[16]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[17]  S. Feldman.  It isn't a perfect world , 2011 .

[18]  H. Nakagawa,et al.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.